
ELEV
Elevation Oncology
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 0
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About ELEV
Elevation Oncology, Inc.
A clinical stage biopharmaceutical company that developing precision medicines for genomically defined cancers
Biological Technology
04/29/2019
06/25/2021
NASDAQ Stock Exchange
34
12-31
Common stock
101 Federal Street, Suite 1900, Boston, Massachusetts 02110
--
Elevation Oncology, Inc., was incorporated under the laws of the State of Delaware on April 29, 2019. The Company is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients with a range of solid tumors with unmet medical needs. The company is rethinking drug development, seeking innovative, selective cancer therapies that can match patients' unique tumor characteristics. The company's lead product candidate, EO-3021 (also known as SYSA 1801 or CPO 102), is an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target that selectively delivers cytotoxic payloads directly to cancer cells expressing Claudin 18.2.
Company Financials
EPS
ELEV has released its 2024 Q4 earnings. EPS was reported at -0.18, versus the expected -0.22, beating expectations. The chart below visualizes how ELEV has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available